Phase I Study of the Novel Investigational NEDD8-activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/refractory Multiple Myeloma or Lymphoma

PURPOSE: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma. EXPERIMENTAL DESIGN:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Shah, Jatin J., Jakubowiak, Andrzej J., O’Connor, Owen A., Orlowski, Robert Z., Harvey, R. Donald, Smith, Mitchell R., Lebovic, Daniel, Diefenbach, Catherine, Kelly, Kevin, Hua, Zhaowei, Berger, Allison J., Mulligan, George, Faessel, Helene, Tirrell, Stephen, Dezube, Bruce J., Lonial, Sagar
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694347/
https://ncbi.nlm.nih.gov/pubmed/26561559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados